Maria Ruzzene

List of Publications by Year
in descending order

112 papers	6,261 citations	71102 41 h-index	71685 76 g-index
114 all docs	114 docs citations	114 times ranked	6235 citing authors

#	Article	IF	Citations
1	Mechanism of CK2 Inhibition by a Ruthenium-Based Polyoxometalate. Frontiers in Molecular Biosciences, 2022, 9, .	3.5	4
2	Protein kinase CK2 inhibition as a pharmacological strategy. Advances in Protein Chemistry and Structural Biology, 2021, 124, 23-46.	2.3	24
3	How can a traffic light properly work if it is always green? The paradox of CK2 signaling. Critical Reviews in Biochemistry and Molecular Biology, 2021, 56, 321-359.	5.2	20
4	Protein kinase CK2: a potential therapeutic target for diverse human diseases. Signal Transduction and Targeted Therapy, 2021, 6, 183.	17.1	145
5	Contribution of the CK2 Catalytic Isoforms Î± and Î±â€™ to the Glycolytic Phenotype of Tumor Cells. Cells, 2021, 10, 181.	4.1	9
6	Targeting CK2 in cancer: a valuable strategy or a waste of time?. Cell Death Discovery, 2021, 7, 325.	4.7	26
7	Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin. FEBS Journal, 2020, 287, 1850-1864.	4.7	9
8	Effects of CK2Î² subunit down-regulation on Akt signalling in HK-2 renal cells. PLoS ONE, 2020, 15, e0227340.	2.5	11
9	A novel class of selective CK2 inhibitors targeting its open hinge conformation. European Journal of Medicinal Chemistry, 2020, 195, 112267.	5.5	15
10	Phosphorylation of p23-1 cochaperone by protein kinase CK2 affects root development in Arabidopsis. Scientific Reports, 2019, 9, 9846.	3.3	5
11	Role of protein kinase CK2 in antitumor drug resistance. Journal of Experimental and Clinical Cancer Research, 2019, 38, 287.	8.6	74
12	The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. Oncogenesis, 2019, 8, 61.	4.9	27
13	PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting. Materials Science and Engineering C, 2019, 103, 109762.	7.3	17
14	Up-Regulation of the Alpha Prime Subunit of Protein Kinase CK2 as a Marker of Fast Proliferation in GL261 Cultured Cells. Pathology and Oncology Research, 2019, 25, 1659-1663.	1.9	6
15	A V1143F mutation in the neuronal-enriched isoform 2 of the PMCA pump is linked with ataxia. Neurobiology of Disease, 2018, 115, 157-166.	4.4	15
16	Therapeutic targeting of CK2 in acute and chronic leukemias. Leukemia, 2018, 32, 1-10.	7.2	74
17	The importance of negative determinants as modulators of CK2 targeting. The lesson of Akt2 S131. PLoS ONE, 2018, 13, e0193479.	2.5	1
18	Under-expression of CK2Î² subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival. Oncotarget, 2018, 9, 5736-5751.	1.8	11

#	Article	IF	Citations
19	Protein kinase CK2 modulates HSJ1 function through phosphorylation of the UIM2 domain. Human Molecular Genetics, 2017, 26, ddw420.	2.9	8
20	Cross-talk between the CK2 and AKT signaling pathways in cancer. Advances in Biological Regulation, 2017, 64, 1-8.	2.3	51
21	The ataxia related G1107D mutation of the plasma membrane Ca 2+ ATPase isoform 3 affects its interplay with calmodulin and the autoinhibition process. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 165-173.	3.8	25
22	Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. Pharmaceuticals, 2017, 10, 24.	3.8	30
23	Role of the protein kinase CK2 in the biology of cholangiocarcinoma cells. Digestive and Liver Disease, 2016, 48, e20.	0.9	1
24	Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB. BioMed Research International, 2015, 2015, 1-9.	1.9	11
25	Phosphorylation, Signaling, and Cancer: Targets and Targeting. BioMed Research International, 2015, 2015, 1-3.	1.9	10
26	CK2 Function in the Regulation of Akt Pathway. , 2015, , 125-140.		0
27	Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity. Biochemical Journal, 2015, 471, 415-430.	3.7	29
28	A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nature Communications, 2015, 6, 7227.	12.8	37
29	Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 1694-1707.	2.3	14
30	Effects of CK2 inhibition in cultured fibroblasts from Type 1 Diabetic patients with or without nephropathy. Growth Factors, 2015, 33, 259-266.	1.7	4
31	<scp>H</scp>elicobacter pylori periplasmic receptor <scp>CeuE</scp> (<scp>HP</scp>1561) modulates its nickel affinity via organic metallophores. Molecular Microbiology, 2014, 91, 724-735.	2.5	35
32	Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential. Cellular and Molecular Life Sciences, 2014, 71, 3173-3185.	5.4	45
33	Casein kinase: the triple meaning of a misnomer. Biochemical Journal, 2014, 460, 141-156.	3.7	102
34	Differential phosphorylation of Akt1 and Akt2 by protein kinase CK2 may account for isoform specific functions. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1865-1874.	4.1	27
35	Synthesis and Properties of a Selective Inhibitor of Homeodomainâ€“Interacting Protein Kinase 2 (HIPK2). PLoS ONE, 2014, 9, e89176.	2.5	23
36	Aberrant signalling by protein kinase CK2 in imatinibâ€resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives. Molecular Oncology, 2013, 7, 1103-1115.	4.6	33

#	Article	IF	Citations
37	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. Journal of Hematology and Oncology, 2013, 6, 78.	17.0	46
38	Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1402-1409.	2.3	21
39	Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation. Biochemical Journal, 2013, 452, 131-137.	3.7	47
40	Biochemical Analysis of the Interactions between the Proteins Involved in the [FeFe]-Hydrogenase Maturation Process. Journal of Biological Chemistry, 2012, 287, 36544-36555.	3.4	33
41	Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stressâ€“Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. Clinical Cancer Research, 2012, 18, 1888-1900.	7.0	71
42	Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia, 2012, 26, 1174-1179.	7.2	94
43	Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells. PLoS ONE, 2012, 7, e49193.	2.5	51
44	Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A. Cellular and Molecular Life Sciences, 2012, 69, 449-460.	5.4	28
45	Phosphoproteomic Profiling of NSCLC Cells Reveals that Ephrin B3 Regulates Pro-survival Signaling through Akt1-Mediated Phosphorylation of the EphA2 Receptor. Journal of Proteome Research, 2011, 10, 2566-2578.	3.7	32
46	Protein kinase CK2 accumulation in â€œoncophilicâ€•cells: causes and effects. Molecular and Cellular Biochemistry, 2011, 356, 5-10.	3.1	21
47	The p23 co-chaperone protein is a novel substrate of CK2 in Arabidopsis. Molecular and Cellular Biochemistry, 2011, 356, 245-254.	3.1	10
48	Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells. BMC Cancer, 2010, 10, 440.	2.6	44
49	Addiction to protein kinase CK2: A common denominator of diverse cancer cells?. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 499-504.	2.3	292
50	Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL. PLoS ONE, 2010, 5, e13552.	2.5	42
51	Assessment of CK2 Constitutive Activity in Cancer Cells. Methods in Enzymology, 2010, 484, 495-514.	1.0	36
52	Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cellular and Molecular Life Sciences, 2009, 66, 3363-3373.	5.4	59
53	Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochemical Journal, 2009, 421, 387-395.	3.7	140
54	Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis. Molecular and Cellular Biochemistry, 2008, 316, 155-161.	3.1	29

#	Article	IF	Citations
55	Phosphorylation of the Saccharomycesâ€ƒcerevisiae Grx4p glutaredoxin by the Bud32p kinase unveils a novel signaling pathway involving Sch9p, a yeast member of the Aktâ€Šâ€ŠPKB subfamily. FEBS Journal, 2008, 275, 5919-5933.	4.7	17
56	The selectivity of inhibitors of protein kinase CK2: an update. Biochemical Journal, 2008, 415, 353-365.	3.7	214
57	Lamin A Ser404 Is a Nuclear Target of Akt Phosphorylation in C2C12 Cells. Journal of Proteome Research, 2008, 7, 4727-4735.	3.7	79
58	pLG72 Modulates Intracellular D-Serine Levels through Its Interaction with D-Amino Acid Oxidase. Journal of Biological Chemistry, 2008, 283, 22244-22256.	3.4	135
59	Salicylic acid activates nitric oxide synthesis in Arabidopsis. Journal of Experimental Botany, 2007, 58, 1397-1405.	4.8	173
60	Heterogeneity of CK2 phosphorylation sites in the NS5A protein of different hepatitis C virus genotypes. Journal of Hepatology, 2007, 47, 768-776.	3.7	15
61	Tetrabromocinnamic Acid (TBCA) and Related Compounds Represent a New Class of Specific Protein Kinase CK2 Inhibitors. ChemBioChem, 2007, 8, 129-139.	2.6	109
62	Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene, 2007, 26, 6915-6926.	5.9	84
63	Phosphorylation and activation of the atypical kinase p53-related protein kinase (PRPK) by Akt/PKB. Cellular and Molecular Life Sciences, 2007, 64, 2680-2689.	5.4	23
64	Role of Protein Kinase CK2 in the Retinoic Acid-Induced Differentiation of Acute Promyelocytic Leukemia Cells.. Blood, 2007, 110, 879-879.	1.4	1
65	Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood, 2006, 108, 1698-1707.	1.4	123
66	The yeast cyclin-dependent kinase inhibitor Sic1 and mammalian p27Kip1 are functional homologues with a structurally conserved inhibitory domain. Biochemical Journal, 2005, 387, 639-647.	3.7	66
67	Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death and Differentiation, 2005, 12, 668-677.	11.2	291
68	Development and exploitation of CK2 inhibitors. Molecular and Cellular Biochemistry, 2005, 274, 69-76.	3.1	87
69	Optimization of Protein Kinase CK2 Inhibitors Derived from 4,5,6,7-Tetrabromobenzimidazole. Journal of Medicinal Chemistry, 2004, 47, 6239-6247.	6.4	168
70	2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochemical and Biophysical Research Communications, 2004, 321, 1040-1044.	2.1	172
71	Inhibition of Protein Kinase CK2 by Condensed Polyphenolic Derivatives. An in Vitro and in Vivo Study. Biochemistry, 2004, 43, 12931-12936.	2.5	87
72	Analysis of the interaction between piD261/Bud32, an evolutionarily conserved protein kinase of Saccharomyces cerevisiae, and the Grx4 glutaredoxin. Biochemical Journal, 2004, 377, 395-405.	3.7	60

#	Article	IF	Citations
73	Multiple Myeloma Cells Survival and Proliferation Rely on High Levels and Activity of the Serine-Threonine Kinase CK2.. Blood, 2004, 104, 643-643.	1.4	2
74	Functional homology between yeast piD261/Bud32 and human PRPK: both phosphorylate p53 and PRPK partially complements piD261/Bud32 deficiency. FEBS Letters, 2003, 549, 63-66.	2.8	34
75	Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochemical Journal, 2003, 374, 639-646.	3.7	145
76	Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity. Biochemical Journal, 2003, 372, 841-849.	3.7	56
77	Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochemical Journal, 2002, 364, 41-47.	3.7	212
78	Increased Activity of c-Src and Csk in Fibroblasts Transformed by v-src Oncogene. Biochemical and Biophysical Research Communications, 2002, 290, 790-795.	2.1	3
79	Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 (â€˜casein kinase-2â€™). FEBS Letters, 2001, 496, 44-48.	2.8	316
80	The carboxy-terminal domain of Grp94 binds to protein kinase CK2Î± but not to CK2 holoenzyme. FEBS Letters, 2001, 505, 42-46.	2.8	11
81	Autocatalytic tyrosine-phosphorylation of protein kinase CK2 Î± and Î±â€² subunits: implication of Tyr182. Biochemical Journal, 2001, 357, 563.	3.7	30
82	Autocatalytic tyrosine-phosphorylation of protein kinase CK2 Î± and Î±â€² subunits: implication of Tyr182. Biochemical Journal, 2001, 357, 563-567.	3.7	36
83	Bovine prion protein as a modulator of protein kinase CK2. Biochemical Journal, 2000, 352, 191.	3.7	29
84	Ser/Thr phosphorylation of hematopoietic specific protein 1 (HS1). FEBS Journal, 2000, 267, 3065-3072.	0.2	18
85	pCMB Treatment Reveals the Essential Role of Cysteinyl Residues in Conferring Functional Competence to the Regulatory Subunit of Protein Kinase CK2. Biochemical and Biophysical Research Communications, 2000, 267, 427-432.	2.1	8
86	Hematopoietic lineage cell specific protein 1 associates with and down-regulates protein kinase CK2. FEBS Letters, 1999, 461, 32-36.	2.8	27
87	Phosphatidylinositol 3-kinase is recruited to a specific site in the activated IL-1 receptor I. FEBS Letters, 1998, 438, 49-54.	2.8	68
88	Spontaneous Autophosphorylation of Lyn Tyrosine Kinase at both Its Activation Segment and C-Terminal Tail Confers Altered Substrate Specificityâ€‚â€¡. Biochemistry, 1998, 37, 1438-1446.	2.5	34
89	Src Homology-2 Domains Protect Phosphotyrosyl Residues against Enzymatic Dephosphorylation. Biochemical and Biophysical Research Communications, 1998, 243, 700-705.	2.1	11
90	Sequence Specificity of C-Terminal Src Kinase (Csk). A Comparison with Src-Related Kinases C-Fgr and Lyn. FEBS Journal, 1997, 246, 433-439.	0.2	30

#	Article	IF	Citations
91	Specific Stimulation of c-Fgr Kinase by Tyrosine-Phosphorylated (Poly)Peptides. Possible Implication in the Sequential Mode of Protein Phosphorylation. FEBS Journal, 1997, 245, 701-707.	0.2	6
92	SH2 Domains Mediate the Sequential Phosphorylation of HS1 Protein by p72syk and Src-Related Protein Tyrosine Kinases. Biochemistry, 1996, 35, 5327-5332.	2.5	54
93	CD45 Regulates Apoptosis Induced by Extracellular Adenosine Triphosphate and Cytotoxic T Lymphocytes. Biochemical and Biophysical Research Communications, 1996, 226, 769-776.	2.1	12
94	How do protein kinases recognize their substrates?. Biochimica Et Biophysica Acta - Molecular Cell Research, 1996, 1314, 191-225.	4.1	444
95	Isolation from Spleen of a 57-kDa Protein Substrate of the Tyrosine Kinase Lyn. Identification as a Protein Related to Protein Disulfide-Isomerase and Localisation of the Phosphorylation Sites. FEBS Journal, 1996, 235, 18-25.	0.2	42
96	A Comparative study of the Phosphotyrosyl Phosphatase Specificity of Protein Phosphatase Type 2A and Phosphotyrosyl Phosphatase Type 1B Using Phosphopeptides and the Phosphoproteins p50/HS1, c-Fgr and Lyn. FEBS Journal, 1996, 236, 548-557.	0.2	17
97	The Spleen Protein-Tyrosine Kinase TPK-IIB is Highly Similar to the Catalytic Domain of p7Psyk. FEBS Journal, 1996, 240, 400-407.	0.2	26
98	Different Susceptibility of Protein Kinases to Staurosporine Inhibition. Kinetic Studies and Molecular Bases for the Resistance of Protein Kinase CK2. FEBS Journal, 1995, 234, 317-322.	0.2	257
99	Site specificity of p72sykprotein tyrosine kinase: efficient phosphorylation of motifs recognized by Src homology 2 domains of the Src family. FEBS Letters, 1995, 367, 149-152.	2.8	71
100	Hierarchical Phosphorylation of a 50-kDa Protein by Protein Tyrosine Kinases TPK-IIB and C-Fgr, and Its Identification as HS1 Hematopoietic-Lineage Cell-Specific Protein. FEBS Journal, 1995, 229, 164-170.	0.2	19
101	Psoralenâ€"fatty acid cycloadducts activate protein kinase C (PKC) in human platelets. Journal of Photochemistry and Photobiology B: Biology, 1994, 22, 253-256.	3.8	15
102	Dephosphorylation of phosphopeptides by calcineurin (protein phosphatase 2B). FEBS Journal, 1994, 219, 109-117.	0.2	83
103	Efficient Fmoc/solidâ€phase peptide synthesis of Oâ€phosphotyrosylâ€containing peptides and their use as phosphatase substrates. International Journal of Peptide and Protein Research, 1994, 43, 39-46.	0.1	25
104	Specificity of T-cell protein tyrosine phosphatase toward phosphorylated synthetic peptides. FEBS Journal, 1993, 211, 289-295.	0.2	55
105	Purification and Characterization of Two Casein Kinases from Ejaculated Bovige Spermatozoa1. Journal of Biochemistry, 1992, 112, 768-774.	1.7	6
106	The antioxidant butylated hydroxytoluene (BHT) inhibits the dioctanoylglycerol-evoked platelet response but potentiates that elicited by Ionomycin. Archives of Biochemistry and Biophysics, 1992, 294, 724-730.	3.0	2
107	The antioxidant butylated hydroxytoluene stimulates platelet protein kinase C and inhibits subsequent protein phosphorylation induced by thrombin. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1094, 121-129.	4.1	9
108	Platelet activation by diacylglycerol or ionomycin is inhibited by nitroprusside. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1094, 323-329.	4.1	20

#	Article	IF	Citations
109	Platelet responses promoted by the activation of protein kinase C or the increase of cytosolic Ca2+ are potentiated by adrenaline. Effects of cAMP and staurosporine. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1092, 72-78.	4.1	11
110	A procedure allowing measurement of cytosolic CA2+ in rat platelets. Inhibition of a plasma lipoprotein on fura 2-AM loading. Thrombosis Research, 1991, 63, 47-57.	1.7	7
111	Cyclic GMP and nitroprusside inhibit the activation of human platelets by fluoroaluminate. Biochimica Et Biophysica Acta - Molecular Cell Research, 1989, 1014, 203-206.	4.1	29
112	Effects of calcium chelators, divalent cations and sulfhydryl reagents on calcium uptake and motility of bovine spermatozoa. Cell Calcium, 1988, 9, 121-128.	2.4	2